Needham & Company LLC Boosts Taysha Gene Therapies (NASDAQ:TSHA) Price Target to $12.00

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective lifted by stock analysts at Needham & Company LLC from $10.00 to $12.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 172.73% from the stock’s previous close.

TSHA has been the subject of a number of other research reports. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Chardan Capital reissued a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday. The Goldman Sachs Group set a $11.00 price target on Taysha Gene Therapies in a research report on Thursday, December 4th. UBS Group set a $11.00 price objective on Taysha Gene Therapies in a research note on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.09.

Taysha Gene Therapies Stock Down 3.5%

Shares of NASDAQ TSHA opened at $4.40 on Thursday. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $6.02. The firm’s 50-day moving average is $4.63 and its 200-day moving average is $4.55. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $1.21 billion, a PE ratio of -12.94 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 62.55%. The business had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. Equities analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the transaction, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at $6,655,853.46. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Sean P. Nolan sold 41,312 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the transaction, the chief executive officer directly owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This trade represents a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 598,623 shares of company stock worth $2,822,188. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. AQR Capital Management LLC grew its stake in Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after acquiring an additional 82,545 shares during the period. Geode Capital Management LLC raised its position in shares of Taysha Gene Therapies by 3.5% during the second quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company’s stock worth $8,765,000 after purchasing an additional 128,840 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth about $1,140,000. Rhumbline Advisers lifted its holdings in shares of Taysha Gene Therapies by 13.5% during the 2nd quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after purchasing an additional 27,794 shares in the last quarter. Finally, Quantum Private Wealth LLC lifted its holdings in shares of Taysha Gene Therapies by 3.1% during the 2nd quarter. Quantum Private Wealth LLC now owns 815,976 shares of the company’s stock valued at $1,885,000 after purchasing an additional 24,500 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Key Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.